宏力醫療管理(09906.HK)年度歸母淨利同比下降55.8%至2184萬元
格隆匯 3 月 25日丨宏力醫療管理(09906.HK)發佈截至2020年12月31日止年度的年度業績公吿,集團的收入同比減少1.3%至人民幣5.24億元,主要是由於治療和綜合醫院服務及藥品銷售產生的收益減少。毛利同比減少19.1%至人民幣1.376億元,毛利率由上年度的32.0%減少至26.3%,主要是由於疫情爆發導致收入減少;而銷售成本中藥品成本增加,疫情防護相關耗材成本增加,人工成本、折舊及攤銷費用及其他成本項目相對固定,導致銷售成本增加,毛利及毛利率降低。公司擁有人應占利潤人民幣2184萬元,同比下降55.8%。每股基本及攤薄盈利人民幣0.04元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.